The following poster categories will be in the Poster Hall:
<ul>
<li>Diagnostics and Biomarkers - MASLD and MASH</li>
<li>Health Disparities/Health Equity Research</li>
<li>MASLD/MASH -Epidemiology and Natural History, Prevention and Outcomes</li>
<li>Hepatitis - Other Infections</li>
<li>Advanced Practice Providers (NP, PA, RN, PharmD, etc.)</li>
<li>Portal Hypertension and Other Complications of Cirrhosis</li>
<li>MASLD/MASH -Treatment: Non-pharmacologic</li>
</ul>

Invitation only!

Join us for a poster highlight of the top abstracts from the Hepatitis C SIG.&nbsp;<br />
&nbsp;

<p>Come discuss the recent International Liver Transplantation Society guideline update on portopulmonary hypertension with one of the authors behind the guideline! Read the guideline here:&nbsp;<br />
<a href="https://journals.lww.com/lt/abstract/9900/international_liver_transplan…;

<p>3:45-3:55 PM- Presentation</p>

<p>3:55-4:15 PM- Audience Q&amp;A and Discussion</p>

<p>&nbsp;</p>

This workshop introduces the concept of point-of-care ultrasonography (POCUS) of the liver as an extension of the clinical exam to be performed by hepatology clinicians. Presenters provide a rationale for the use of POCUS, the basics of liver ultrasonography, common applications, and a path to implement POCUS in clinical practice. Participants will also receive hands-on training on performing point-of-care ultrasound examinations of the liver.<br />
<br />
<em>This session is supported by in-kind contributions (provision of ultrasound equipment) from GE Healthcare, Mindray, NEO Medical, and Siemens Healthineers.</em><br />
&nbsp;

The clinical significance of findings in liver biopsies exhibiting steatotic liver disease (MASLD, MetALD, MASH) are the focus of this session. Presentations and discussion examine some of the interpretive issues that pertain to the new steatotic liver disease category MetALD, ie, whether it is feasible to distinguish contribution or features of alcohol-related findings from MASLD only or MASH only. Metabolic diseases (eg,&nbsp;Wilson disease or alpha-1 antitrypsin deficiency) and DILI with a steatohepatitic pattern (eg, methotrexate) are discussed with an emphasis on distinguishing these entities from other categories of steatotic liver disease. In addition to pathology, the session highlights the importance of utilization of pathology reports to facilitate diagnosis and further work-up, and the utility and limitations of liver biopsy to narrow a differential diagnosis. Case presentations illustrate the importance of clinicopathologic correlation in different clinical settings.&nbsp;<br />
<br />
&nbsp;

<p>What are the pros, cons, knowns, and unknowns of HCC immunotherapy in liver transplantation? Come discuss with Liver Transplantation Associate Editor Dr. Kymberly Watt. Read the recent HEPATOLOGY article and its editorial here: &nbsp;<a href="https://journals.lww.com/hep/fulltext/9900/check_point_s_and_balances__… />
<a href="https://journals.lww.com/hep/abstract/9900/determining_safe_washout_per…;

<p>12:45-12:55 PM- Presentation</p>

<p>12:55-1:15 PM- Audience Q&amp;A and Discussion</p>

MASLD, Obesity, Cardiometabolic Syndrome, T2DM are all overlapping yet distinct diseases. Follow a patient in real time from primary to tertiary care. Challenge the experts in hepatology, cardiology and obesity medicine as they debate the latest research and missed opportunities along the patient&rsquo;s journey: Juggle polypharmacy, lifestyle interventions, biomarkers, multimodal imaging. Interactive Evening Symposium. Dinner and Refreshments provided.<br />
<br />
For more information and to register, visit:&nbsp;<a href="https://healthpromatch.com/courseRegistration/?courseId=6">https://heal… />
<br />
Supported by:&nbsp;Perspectum Ltd<br />
<br />
Organized by: HealthProMatch<br />
<br />
Important Note: Continuing education credits for Satellite Symposia are offered by the sponsoring organizations. These sessions are not accredited by AASLD.

The Ipsen-sponsored TLM Theatre will explore current approaches to the management of Biliary Atresia, highlighting opportunities for further optimization of care and patient outcomes. Prognostic biomarkers and the underlying pathophysiology driving disease progression in Biliary Atresia will also be addressed.<br />
<br />
Industry Supporter:&nbsp;Ipsen Biopharmaceuticals<br />
<br />
&nbsp;

Recognizing the ongoing challenges faced by LGBTQ+ individuals and underrepresented minorities (URMs) in health care, particularly amidst recent shifts in funding, policy, and societal attitudes, this community conversation session aims to address systemic barriers contributing to disparities in health care access and outcomes for these populations. The session highlights specific challenges, such as how changes in funding and policies may impact diversity, equity, and inclusion (DEI) initiatives in academic and health care settings. Strategies to sustain and enhance diverse workforce recruitment despite evolving regulations and restrictions are explored. Panelists also address new challenges facing LGBTQ+ patients and health care practitioners, including barriers to accessing equitable liver care and the broader implications of these obstacles on their health and well-being. By bringing together DEI leaders from academic institutions and frontline health care workers, this conversation seeks to identify practical solutions that ensure ongoing support for LGBTQ+ and URM individuals as both patients and health care practitioners. The ultimate goal is to foster a more inclusive hepatology community where diversity is not only acknowledged but celebrated, ensuring equitable health care delivery and professional opportunities for all.